BRAF-amplified glioblastoma patients have a worse prognosis than those with BRAF mutation and are associated with amplification of MET, RHEB and CUL1.

Abstract excerpt

BACKGROUND: Glioblastoma (GBM) is a treatment-challenging disease with a poor prognosis and few treatment options available. Patients with GBM with BRAF gene mutations are expected to benefit from targeted therapy with BRAF inhibitors. METHODS: Genomic profiles, clinical and sample data, and tumor pathways were retrieved in a cohort of GBM patients with BRAF gene alterations. Statistical analysis was performed...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Brain Neoplasms
• Share to Cullin Proteins
• Share to Gene Amplification